Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors

@inproceedings{PlssonMcDermott2017PyruvateKM,
  title={Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors},
  author={Eva M. P{\aa}lsson-McDermott and Lydia Dyck and Zbigniew Zasłona and Deepthi Menon and Anne F. McGettrick and Kingston H G Mills and Luke A. J. O’Neill},
  booktitle={Front. Immunol.},
  year={2017}
}
Blocking interaction of the immune checkpoint receptor PD-1 with its ligand PD-L1 is associated with good clinical outcomes in a broad variety of malignancies. High levels of PD-L1 promote tumor growth by restraining CD8+ T-cell responses against tumors. Limiting PD-L1 expression and function is therefore critical for allowing the development of antitumor immune responses and effective tumor clearance. Pyruvate kinase isoform M2 (PKM2) is also a key player in regulating cancer as well as immune… CONTINUE READING